What question did this study set out to answer?

Evaluate zanubrutinib maintenance therapy in PCNSL patients who achieved complete response and refused autologous stem cell transplantation.

December 8, 2025Blood

Efficacy of zanubrutinib maintenance in patients with primary CNS lymphoma achieving complete response: A phase II study

View Full Paper

Ask AI

Bookmark

Authors

Phase II study finds zanubrutinib maintenance improves progression-free survival in PCNSL, suggesting benefits in treatment efficacy.

Evaluate zanubrutinib maintenance therapy in PCNSL patients who achieved complete response and refused autologous stem cell transplantation.
Patients received MTX-based chemotherapy for PCNSL then maintained with zanubrutinib for 1 year after achieving CR.
Clinical data on remission status, relapse, and survival outcomes were collected and analyzed.
Primary endpoint was progression-free survival, secondary endpoints included overall response rate and overall survival.
CR rate after 6 months of maintenance therapy was 87.5%.
Estimated 6-month PFS rate was 87.5%, while the 12-month PFS rate was 72.9%.
Estimated 12-month OS rate was 100%, with a 24-month OS rate of 66.7%.
No adverse events leading to dose modifications were observed.

Bobin Chen (2025) studied this question.

View Full Paper

Ask AI

Bookmark